

# Rare but Deadly TTP Can Masquerade as HELLP

BY SARAH PRESSMAN  
LOVINGER  
Contributing Writer

CHICAGO — You are caring for a gravid woman with very low platelets and hemolytic anemia. You diagnose her with HELLP syndrome and order a platelet transfusion. Is this the best management of a pregnant patient with thrombocytopenia at risk of bleeding?

Not always, according to Dr. James J. Martin Jr. of the University of Mississippi Medical Center in Jackson.

Thrombotic thrombocytopenic purpura (TTP) can masquerade as HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome. Administering platelets to any patient with this rare but often fatal hematologic disorder can

**If physicians mistake TTP for HELLP syndrome and administer one or more platelet transfusions, they may aggravate the hemolytic state.**

paradoxically worsen the patient's condition, leading to severe disability and death.

Physicians must always consider TTP when caring for pregnant women who present with low platelets.

"Obstetricians-gynecologists are really in a quandary," Dr. Martin said at the annual meeting of the Central Association of Obstetricians and Gynecologists.

"The main problem is differentiating between TTP and HELLP," he said. "You need to do it right away," he added.

While TTP is an extremely rare disease that affects only 4-11 patients per million population, the combination of low platelets, hemolytic anemia, renal failure, and mental status changes can be deadly if undiagnosed.

If physicians mistake TTP for HELLP syndrome and administer one or more platelet transfusions, they may aggravate the hemolytic state caused by absent or severely low levels of a von Willebrand factor-cleaving protease, a potentially fatal error.

Plasma therapy can help replete this protease—known as ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13—and stop the destructive hemolysis that TTP causes. Maternal mortality caused by TTP can drop to less than 10% in women properly treated with plasma therapy.

Obstetricians lack a straightforward method to differentiate between TTP and HELLP syndrome. "We need a definite test for TTP," said Dr. Martin.

To obtain more information about lab findings in pregnant women that could shed light on possible tests to ease diagnosis of these confounding disorders, Dr. Martin and his colleagues performed an extensive English-language literature search of pregnant patients with TTP, and uncovered 166 reported cases from 1955 to

2006. They excluded patients with hemolytic-uremic syndrome, postpartum renal failure, or severe preeclampsia/eclampsia/HELLP syndrome who lacked reasonable information that could diagnose TTP.

The researchers uncovered only seven papers published between 2002 and 2006 looking at ADAMTS-13 activity levels in suspected TTP patients. Additional analysis revealed that several common lab tests could help differentiate women who have

TTP only from women who have TTP together with preeclampsia/HELLP syndrome. The researchers found that the ratio of lactate dehydrogenase (LDH) to serum glutamic oxaloacetic transaminase (SGOT) levels was considerably higher in patients with TTP only, compared to women with combined TTP/preeclampsia/HELLP syndrome.

Dr. Martin recommends testing for ADAMTS-13 levels in pregnant patients who have a LDH/SGOT ratio that ex-

ceeds 15. He also recommends this test early in pregnancy in women who have a history of TTP.

A rapid, reliable lab test could help physicians distinguish more easily between the common preeclampsia/HELLP syndromes and TTP, the deadly masquerader. Until then, physicians must keep in mind that pregnant patients who present with low platelets and hemolytic anemia could have TTP and act accordingly, Dr. Martin said. ■

## IT'S A QUESTION WORTH ASKING.

Only RhoGAM®, the leading\* Rh<sub>0</sub>(D) Immune Globulin brand, offers all of these benefits:

- A 39-year history of safety and reliability
  - No documented cases of viral transmission
  - No interruptions in product supply
- A select pool of dedicated, long-standing plasma donors
- Dosing guidelines that align with ACOG standards
- Robust viral inactivation (including West Nile virus) and removal (including hepatitis A) processes to minimize risk of viral transmission
- A product free of latex, thimerosal, and human serum albumin

### Important Safety Information

RhoGAM® and MICRhoGAM® Ultra-Filtered PLUS Rh<sub>0</sub>(D) Immune Globulin (Human) are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. RhoGAM and MICRhoGAM are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. RhoGAM and MICRhoGAM contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM or MICRhoGAM for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

\*in the U.S. (Data on file. Ortho-Clinical Diagnostics)

For more detailed information concerning the safe and effective use of RhoGAM® Brand, see the accompanying brief summary of prescribing information.

visit [rhogam.com](http://rhogam.com) to learn more

 Ortho-Clinical Diagnostics  
a Johnson & Johnson company

© Ortho-Clinical Diagnostics, Inc. 2007 BB10217A 1107 Printed in U.S.A.

IS SHE  
REALLY  
GETTING  
RHO GAM?

 RhoGAM®  
Ultra-Filtered PLUS  
Rh<sub>0</sub>(D) Immune Globulin (Human)

There is only ONE RhoGAM®